Global Anti-epileptic Drugs for Pediatrics Market Professional Survey Report 2019

Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Depending on the area of the brain obstructed by seizures, these are categorized into generalized seizures and partial seizures. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Depending on their severity, seizures are termed as mild seizures and stronger seizures. Mild seizures are difficult to diagnose, as these last for only a few seconds. Stronger seizures may last for a few seconds to a few or several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.

The global Anti-epileptic Drugs for Pediatrics market was valued at 830 million US$ in 2018 and will reach 1530 million US$ by the end of 2025, growing at a CAGR of 7.9% during 2019-2025.
This report focuses on Anti-epileptic Drugs for Pediatrics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Anti-epileptic Drugs for Pediatrics market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Anti-epileptic Drugs for Pediatrics in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Anti-epileptic Drugs for Pediatrics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Mylan N.V
Cephalon, Inc
GlaxoSmithKline plc
Janssen Pharmaceuticals
Novartis AG
Pfizer, Inc
Sanofi S.A
UCB Pharma Limited
Sunovion Pharmaceuticals Limited
Valeant Pharmaceuticals International, Inc
Zogenix
GW Pharmaceuticals
Insys
Zynerba

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
1st generation
2nd generation
3rd generation

Segment by Application
Hospitals
Retail pharmacies
Online pharmacies